Clinical Pharmacology and Pharmacy, 2022 (vol. 36), issue 2
Original articles
Cost-effectiveness analysis of biological drugs in treating moderate to severe plaque psoriasis from the perspective of a health service provider
Jaroslav Duda
Klin Farmakol Farm. 2022;36(2):54-67 | DOI: 10.36290/far.2022.010 
Introduction: Psoriasis is a chronic disease with a number of significant comorbidities, often having a very substantial impact on the quality of life of patients. Recently, a relatively high number of biological therapy agents have been introduced to the market; however, compared to systemic conventional treatment, they are much more expensive. In the context of a reported long period of inadequate treatment of psoriasis patients in the Czech Republic, system of health care, and limited costs for medicines used in specialized centres, every effort must be made at the very level of the health care provider to spend financial resources effectively and...
Main topic
Clinical experience with facilitated subcutaneous immunoglobulin treatment
Zita Chovancová
Klin Farmakol Farm. 2022;36(2):38-42 | DOI: 10.36290/far.2022.007
The immunoglobulin replacement therapy serves to compensate for the insufficient production of opsonizing and neutralizing antibodies against a wide range of pathogens in patients with congenital or acquired antibody production disorders. The basic routes of administration include intravenous, conventional subcutaneous and subcutaneous administration facilitated by hyaluronidase (fSCIG). Subcutaneous administration of this enzyme at the beginning of the treatment allows to temporarily grind the extracellular matrix and thus use the volume of normal human immunoglobulin in the dose and interval of administration as in intravenous route of administration...
Lanadelumab in hereditary angioedema treatment
Marta Sobotková
Klin Farmakol Farm. 2022;36(2):43-47 | DOI: 10.36290/far.2022.008
Hereditary angioedema is a rare disorder associated with recurrent episodes of swellings in different body areas. C1 inhibitor deficiency is the most common cause of this disease. Bradykinin is considered to be the main mediator responsible for angioedema formation. Fully human monoclonal antibody lanadelumab targets plasma kalikrein, which is responsible for bradykinin formation. It is currently registered for long term prophylaxis in hereditary angioedema and represents a highly effective and well tolerated treatment option in patients with frequent and severe swellings.
Is it possible to influence the onset and course of COVID-19 infection? (Results of a study by nurses at the University Hospital Ostrava)
Jaromír Bystroň, Tomáš Balner, Jana Kačorová
Klin Farmakol Farm. 2022;36(2):48-53 | DOI: 10.36290/far.2022.009
A pilot monocentric study evaluated the effect of Imunor on the prevention of COVID-19 in 51 nurses at the University Hospital Ostrava during the third wave of the COVID-19 pandemic (delta variant) in the Czech Republic. The primary objective of the study was to determine whether regular administration of Imunor for 1 month, 2 months, and 1 month after discontinuation prevented SARS-CoV2 infection in nurses working in outpatient and inpatient settings in high-risk environments. with patients with COVID-19. The secondary objective of the study was to evaluate whether the course of the disease would be milder in COVID-19. The need for hospitalization...
Review articles
Melatonin in the management of sleep disorders associated with atopic dermatitis - from theory to practice
MUDr. Paula Ďuríková
Klin Farmakol Farm. 2022;36(2):68-71 | DOI: 10.36290/far.2022.011
Melatonin is an evolutionarily conserved indolamine with a wide range of biological functions. Its dominant role is the chronobiological regulation of the sleep-wake cycle, while its sedative effect is successfully used in the management of primary sleep disorders. However, melatonin is also a powerful antioxidant and it acts as an immunoregulatory molecule at several levels of immune system. Sleep disorders play an important role in the context of reduced quality of life associated with skin disease. Based on the current findings on the multimodal action of the central and peripheral melatoninergic system, it is plausible to assume the efficacy of...
Pharmacological profile
Vericiguat: pharmacological profile
Karel Urbánek
Klin Farmakol Farm. 2022;36(2):77-80 | DOI: 10.36290/far.2022.013
Vericiguat is a new drug for the treatment of chronic heart failure. It acts as a direct sGS stimulator whose activity is not dependent on the presence of NO. It is administered orally once daily at doses of 2.5, 5 and 10 mg with gradual upward titration. It is metabolized by hepatic glucuronidases UGT1A9 and 1A1 to inactive N-glucuronide. Approximately 53 % of the administered dose is excreted in the urine, while 45% in the faeces. The biological elimination half-life in healthy volunteers averaged 20 hours and in patients with heart failure averaged 30 hours. Its most common adverse effect with an incidence of about 16% is hypotension. It has minimal...
Case reports
Preventive treatment of migraine in elderly patients, is fremanezumab light at the end of the tunnel?
Lucia Mokošová
Klin Farmakol Farm. 2022;36(2):72-76 | DOI: 10.36290/far.2022.012
The case report presents a case of a polymorbid 69-year-old patient with chronic migraine, with practically impossibility of setting for non-specific preventive oral treatment. An asymptomatic hemangioblastoma in the left cerebellum was accidentally detected in the patient, which was completely resected and, despite the patient's strong expectations, had no effect on the frequency and intensity of migraine headaches. After initiation and regular monthly administration of fremanezumab, significant efficacy and a breakthrough impact on the patient's quality of life were noted.